Table 1.
Carotid artery plaques at baseline (n. 1168) (*) |
New carotid artery plaques at follow-up (n. 486) (†) |
|||||
---|---|---|---|---|---|---|
Presence | Absence | Presence | Absence | |||
n. 538 (46.1%) | n. 630 | p (‡) | n. 195 (40.1%) | n. 291 | p (‡) | |
General characteristics | ||||||
Age (years) (mean ± SD) | 75.5 ± 8.3 | 61.7 ± 17.2 | < 0.001 | 71.2 ± 7.2 | 56.6 ± 16.9 | < 0.001 |
Sex (% females) | 49.6 | 60.0 | < 0.001 | 59.5 | 58.4 | 0.576 |
Chronic respiratory, urinary tract and dental Infections (%) | 49.7 | 33.4 | 0.316 | 43.7 | 24.7 | 0.260 |
Use of statins and/or antiinflammatory drugs (%) | 13.0 | 8.9 | 0.451 | 11.8 | 7.2 | 0.987 |
Cardiovascular risk factors | ||||||
Family medical history of atherosclerosis (%) | 51.0 | 43.5 | 0.011 | 55.9 | 37.1 | 0.024 |
Physical activity level previous year (score 0-4, 4 best) (mean ± SD) | 1.29 ± 0.89 | 1.51 ± 0.87 | 0.612 | 1.35 ± 0.74 | 1.71 ± 0.86 | 0.337 |
BMI (kg/m2) (mean ± SD) | 27.5 ± 3.7 | 27.1 ± 4.4 | 0.628 | 27.9 ± 4.2 | 26.7 ± 4.4 | 0.891 |
Pack-years Index (mean ± SD) | 15.1 ± 22.1 | 7.6 ± 14.4 | < 0.001 | 10.5 ± 17.2 | 5.5 ± 9.9 | 0.001 |
Total Cholesterol (mg/dL) (mean ± SD) | 219.2 ± 39.4 | 212.6 ± 40.1 | 0.173 | 221.1 ± 36.3 | 210.1 ± 41.6 | 0.637 |
LDL-Cholesterol (mg/dL) (mean ± SD) | 138.5 ± 33.7 | 132.0 ± 35.7 | 0.138 | 141.1 ± 32.2 | 129.8 ± 37.4 | 0.818 |
HDL-Cholesterol (mg/dL) (mean ± SD) | 54.5 ± 15.1 | 56.0 ± 14.4 | 0.687 | 54.2 ± 12.5 | 56.9 ± 14.8 | 0.269 |
Triglycerides (mg/dL) (mean ± SD) | 130.6 ± 72.4 | 123.3 ± 82.6 | 0.795 | 128.5 ± 65.9 | 117.2 ± 69.4 | 0.416 |
Diabetes (%) | 13.5 | 6.3 | 0.021 | 9.7 | 2.6 | 0.104 |
Hypertension (%) | 77.1 | 49.2 | < 0.001 | 62.2 | 36.0 | 0.780 |
Metabolic Syndrome (%) | 25.6 | 18.5 | 0.135 | 20.8 | 16.4 | 0.280 |
Coronary artery disease (%) | 9.5 | 3.2 | 0.080 | 6.6 | 0.3 | 0.037 |
Perpheral artery disease (%) | 16.3 | 4.0 | 0.001 | 5.2 | 1.0 | 0.094 |
Inflammatory markers | ||||||
C-reactive protein high sensitivity (μg/mL) (mean ± SD) (§) | 5.89 ± 10.81 | 3.76 ± 6.56 | 0.006 | 4.45 ± 5.30 | 2.57 ± 3.56 | 0.005 |
Interleukin 1-β (pg/mL) (mean ± SD) (§) | 0.28 ± 1.34 | 0.32 ± 1.80 | 0.342 | 0.29 ± 1.77 | 0.29 ± 1.48 | 0.286 |
Interleukin 1 receptor antagonist (pg/mL) (mean ± SD) (§) | 162.9 ± 124.0 | 152.6 ± 125.0 | 0.798 | 154.4 ± 94.8 | 143.0 ± 106.6 | 0.192 |
Interleukin 6 (pg/mL) (mean ± SD) (§) | 2.32 ± 4.41 | 1.52 ± 1.80 | 0.516 | 1.70 ± 1.51 | 1.21 ± 1.77 | 0.172 |
Interleukin 6 soluble receptor (ng/mL) (mean ± SD) (§) | 105.0 ± 55.6 | 99.3 ± 58.6 | 0.148 | 102.7 ± 59.7 | 99.5 ± 61.7 | 0.341 |
Tumor necrosis factor α (pg/mL) (mean ± SD) (§) | 3.85 ± 6.00 | 3.02 ± 3.92 | 0.891 | 3.22 ± 4.14 | 2.69 ± 3.55 | 0.672 |
Participants with complete data at baseline.
Participants free from carotid artery plaques at baseline who received a carotid artery scan at three-year follow-up.
From age- and sex-adjusted linear or logistic regressions, as appropriate.
Variables log-transformed before being entered into regressions due to marked skewness.